The Kadans B900 Building is a recently developed, high quality bio- and chemistry laboratory facility on Babraham Research Campus in Cambridge. The 4000 sqm building consists of two floors with both modern office spaces and laboratories dedicated to biotechnical research. The development of the building was initiated by Imperial College Thinkspace in 2015, designed by B3 architects and completed in 2017. Kadans acquired the building early 2019.
Current tenants of the B900 Building include Abzena and Bicycle Therpeutics. Both companies are specialized in developing new types of cutting-edge medications / treatments and related technologies in the field of cancer and immunology. Abzena offers a range of complementary services and technologies for the selection, development and production of biopharmaceuticals based on antibodies or other proteins. Bicycle Therapeutics is a highly innovative biotechnology company active in research of bio-therapeutics and oncology treatment technologies. The company was co-founded by Sir Gregory Winter, Cambridge University Professor and Nobel Prize winner in Chemistry.